Clinical neurology and neurosurgery · 2025
Mid-long term efficacy of dihydroergotoxine mesylate in treatment of sialorrhea in Parkinson's disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jin Huihui, Huang Ting, Wu Jing, Zhu Yanan, Gao Qing, Tian Youyong
Аннотация
PURPOSE: To further assess the mid-long term effects of dihydroergotoxine mesylate (DHM) on salivation in patients with Parkinson's disease (PD).
METHODS: Thirty-nine participants were enrolled in a 24-week, open, self-controlled study. After baseline assessments of salivation, swallowing, and motor and cognitive function, the participants were given DHM. The primary outcome was the difference in the Sialorrhea Clinical Scale for Parkinson's disease (SCS-PD) scores of salivation before and after treatment. The secondary outcomes included ≥ 30 % improvement in the SCS-PD score at each posttreatment visit and changes in the scores from other scales.
RESULTS: A total of 39 participants were included in this study, and 4 participants dropped out. Finally, 35 patients completed all the visits. Salivation: After treatment for 1 week, the primary outcome, namely, the median SCS-PD score, decreased from 9.0 (IQR 5.0-12.0) at baseline to 7.0 (IQR 4.7-10.0) (P = 0.03). This effect persisted at 24 weeks, and the median score at 24 weeks was 5.0 (IQR 2.0-8.0) (P < 0.001 compared with baseline). For the Drooling Severity and Frequency Scale (DSFS) scale, the median baseline score was 6.0 (IQR 5.0-7.0). After two weeks of treatment, the median score decreased from baseline to 5.0 (IQR 4.0-6.0) (P < 0.001), and the median score at the final visit was 4.0 (IQR 3.7-6.0) (P < 0.001). The second term of the second part of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS-2.2) showed a trend that was consistent with that of the DSFS scale, and significant differences started to emerge at 2 weeks after treatment was initiated. Within one week of treatment, 25.64 % of the patients had improved SCS-PD scores, reaching improvements of 30 % or more. At 2-12 weeks, the proportion of patients with improved SCS-PD scores exceeded 50 %, and this proportion reached 64.10 % at 24 weeks. Swallowing function: The Eating Assessment Tool-10 (EAT-10) revealed that the median scores at 4-24 weeks were 1.0 (IQR 0-3.0), 1.0 (IQR 0-2.2) and 1.0 (IQR 0-3.0), which were significantly different from the baseline score of 2.0 (IQR 0.7-4.0) (P < 0.05). After 2 weeks of treatment, the median score of the Swallowing Disturbance Questionnaire for Parkinson's Disease (SDQ-PD) decreased from 22.0 (IQR 18.0-27.0) at baseline to 19.0 (IQR 17.0-23.2) (P = 0.001). However, motor and cognitive function did not significantly change in this study. Moreover, only 7.69 % of patients experienced mild and transient adverse effects.
CONCLUSION: DHM can significantly ameliorate salivation in PD patients over 24 weeks, with fewer adverse effects.
METHODS: Thirty-nine participants were enrolled in a 24-week, open, self-controlled study. After baseline assessments of salivation, swallowing, and motor and cognitive function, the participants were given DHM. The primary outcome was the difference in the Sialorrhea Clinical Scale for Parkinson's disease (SCS-PD) scores of salivation before and after treatment. The secondary outcomes included ≥ 30 % improvement in the SCS-PD score at each posttreatment visit and changes in the scores from other scales.
RESULTS: A total of 39 participants were included in this study, and 4 participants dropped out. Finally, 35 patients completed all the visits. Salivation: After treatment for 1 week, the primary outcome, namely, the median SCS-PD score, decreased from 9.0 (IQR 5.0-12.0) at baseline to 7.0 (IQR 4.7-10.0) (P = 0.03). This effect persisted at 24 weeks, and the median score at 24 weeks was 5.0 (IQR 2.0-8.0) (P < 0.001 compared with baseline). For the Drooling Severity and Frequency Scale (DSFS) scale, the median baseline score was 6.0 (IQR 5.0-7.0). After two weeks of treatment, the median score decreased from baseline to 5.0 (IQR 4.0-6.0) (P < 0.001), and the median score at the final visit was 4.0 (IQR 3.7-6.0) (P < 0.001). The second term of the second part of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS-2.2) showed a trend that was consistent with that of the DSFS scale, and significant differences started to emerge at 2 weeks after treatment was initiated. Within one week of treatment, 25.64 % of the patients had improved SCS-PD scores, reaching improvements of 30 % or more. At 2-12 weeks, the proportion of patients with improved SCS-PD scores exceeded 50 %, and this proportion reached 64.10 % at 24 weeks. Swallowing function: The Eating Assessment Tool-10 (EAT-10) revealed that the median scores at 4-24 weeks were 1.0 (IQR 0-3.0), 1.0 (IQR 0-2.2) and 1.0 (IQR 0-3.0), which were significantly different from the baseline score of 2.0 (IQR 0.7-4.0) (P < 0.05). After 2 weeks of treatment, the median score of the Swallowing Disturbance Questionnaire for Parkinson's Disease (SDQ-PD) decreased from 22.0 (IQR 18.0-27.0) at baseline to 19.0 (IQR 17.0-23.2) (P = 0.001). However, motor and cognitive function did not significantly change in this study. Moreover, only 7.69 % of patients experienced mild and transient adverse effects.
CONCLUSION: DHM can significantly ameliorate salivation in PD patients over 24 weeks, with fewer adverse effects.